Drug intelligence / Profile preview

CT-04

Development stage: Preclinical
Lead developer: Captor Therapeutics
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics

Overview

CT-04 is an investigational anti-inflammatory therapeutic being developed by Celestial Therapeutics, Inc. The drug is built upon the company's proprietary Stellar mRNA platform, which is designed to create dual-modal therapeutics with both antiviral and anti-inflammatory properties. While Celestial Therapeutics has disclosed that CT-04 is part of its early-stage pipeline for the treatment of inflammatory conditions, specific molecular targets and primary clinical indications remain undisclosed as of early 2024. The candidate is currently in the pre-clinical or early clinical stages of development.

Targets

ROCK2 (Rho-associated coiled-coil containing protein kinase 2)

Beyond the preview

Go deeper on CT-04.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT-04.

Explore the full profile